Minghui Pharmaceutical
Minghui Pharmaceutical is a China-based biotechnology company that leads 9 cancer trials in OnCo, testing its MHB-series antibody-drug conjugates and the bispecific antibody MHB039A in prostate cancer and advanced solid tumours.
Overview
Minghui Pharmaceutical is a Hangzhou-based biopharmaceutical company. The ClinicalTrials.gov registry lists it as lead sponsor of trials of its antibody-drug conjugates MHB009C, MHB036C, MHB042C, MHB046C, MHB048C and MHB088C and of the bispecific antibody MHB039A in advanced solid tumours. No company website could be verified, so company facts here are limited to the registry. On ClinicalTrials.gov it is the lead sponsor of 9 trials recorded in OnCo: NCT07326488 (phase 1/2, A Study of MHB009C in Patients With Advanced Solid Tumors), NCT07229599 (phase 1/2, A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Ca...), NCT07130383 (phase 2, A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Oth...), NCT06373406 (phase 1/2, A Study of MHB036C for Advanced Solid Tumor), NCT06345482 (phase 1/2, A Study of MHB039A for Advanced Solid Tumor), NCT07192107 (phase 1/2, A Study of MHB042C in Patients With Advanced Solid Tumors), NCT06985355 (phase 1/2, A Study of MHB046C Injection in Patients With Advanced Solid Tumors), NCT07192120 (phase 1/2, A Study of MHB048C in Patients With Advanced Solid Tumors) and NCT07126665 (phase 1/2, A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Scorecard
All companies- approved products +12
- phase 3 +3
- phase 1/2 +2
- targets +4
- modalities +8
- regions +6
- registry trials +30
Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.
Carboplatin is a platinum chemotherapy that crosslinks DNA; it is part of the standard pre-surgery regimen for triple-negative breast cancer.
MHB039A is a bispecific antibody from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.
MHB036C is an antibody-drug conjugate from Minghui Pharmaceutical (Hangzhou) Ltd, in registered phase 2 trials for metastatic cancer.
QLC5508 is an experimental antibody-drug conjugate from Qilu Pharmaceutical in phase 3 trials for oesophageal cancer, prostate cancer and non-small-cell lung cancer, aimed at B7-H3.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Shares QLC5508, Prostate cancer.
- TrialA Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Shares QLC5508, Carboplatin.
- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Furmonertinib, Carboplatin.
- TrialA Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Furmonertinib, Carboplatin.